Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-life Treatment Outcomes of Ravulizumab in Polish Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH). Prospective and Retrospective, Multicenter, Non-interventional Study.

NCT06633536 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06633536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06633536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-life Treatment Outcomes of Ravulizumab in Polish Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH). Prospective and Retrospective, Multicenter, Non-interventional Study.
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Active, not recruiting
Start date
February 6, 2025
Completion date
August 1, 2028
Enrollment
64 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal nocturnal haemoglobinuria